Monopar Therapeutics Inc. (NASDAQ: MNPR) reported Q4 EPS of ($0.22), $0.01 worse than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Monopar Therapeutics Inc. (MNPR) click here.